EVGN: Evogene Ltd. - Summary | Jitta

Evogene Ltd.

ISR:EVGN

Price
₪2.32
Loss Chance
57.9%
1.38JITTA SCORE
100.00%Over Jitta Line
Jitta Ranking
385 / 421
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (38)
Recent Business Performance (28)
Financial Strength (30)
Return to Shareholders (13)
Competitive Advantage (33)
Jitta Signs
SG&A to SalesDecreasing Every Year
Revenue and EarningEarning loss detected in 2025
Operating MarginDeclined
Recent Business PerformanceEarning decline 851.62% in the last quarter (yoy)
New Share IssuedMore than 50% in 5 years
CapExVery High
Key Stats
Jitta Score
Jitta Line
1.38
100.00%
1.58
85.44%
2.84
95.01%
Biotechnology
1.84
100.00%
n/a
100.00%
0.58
100.00%
COMPANY DESCRIPTION
Evogene Ltd., together with its subsidiaries, operates as a computational biology company in Israel, the United States, Europe, and Africa. It operates through three segments: Agriculture, Human Health, and Industrial Applications. The company engages in the agricultural activities, including seed traits and ag-chemicals activities; and design novel small molecules for drug development by utilizing ChemPass AI, a computational generative AI engine. It also focuses on the development and commercialization of castor bean seeds for industrial uses. In addition, the company medical cannabis products. It has a collaboration with LMU University Hospital Munich to develop novel therapies for hyper-inflammatory diseases driven by dysregulated neutrophil activity, including inflammatory bowel disease (IBD). The company was incorporated in 1999 and is headquartered in Rehovot, Israel.